Thyroid carcinoma is the most frequent endocrine malignant neoplasm even if a rare occurrence (0.5%-1.0%) of all human malignant tumors. Primary differentiated (papillary and follicular) forms represent over 90% of the total. Since recurrence of thyroid carcinoma can occur even after several years, patients must undergo a life-long follow-up. Thyroglobulin, being organ-specific, plays a major role as tumor marker and it is used essentially in the monitoring and follow-up of patients with differentiated thyroid carcinoma, both during L-thyroxine suppressive therapy and when it is discontinued or after recombinant TSH administration. The presence of antithyroglobulin antibodies masks the real value of thyroglobulin and therefore, at the same time, antithyroglobulin antibodies should always be determined.

Maussier, M. L., Danese, D., D'errico, G. F. L., Garganese, M., Pontecorvi, A., Lemmo, G., Clinical and laboratory follow-up in differentiated thyroid carcinoma, <<RAYS>>, 2000; 25 (2): 239-244 [http://hdl.handle.net/10807/13213]

Clinical and laboratory follow-up in differentiated thyroid carcinoma

Maussier, Maria Lodovica;D'Errico, Giovanni Francesco Livio;Pontecorvi, Alfredo;Lemmo, Gianfranco
2000

Abstract

Thyroid carcinoma is the most frequent endocrine malignant neoplasm even if a rare occurrence (0.5%-1.0%) of all human malignant tumors. Primary differentiated (papillary and follicular) forms represent over 90% of the total. Since recurrence of thyroid carcinoma can occur even after several years, patients must undergo a life-long follow-up. Thyroglobulin, being organ-specific, plays a major role as tumor marker and it is used essentially in the monitoring and follow-up of patients with differentiated thyroid carcinoma, both during L-thyroxine suppressive therapy and when it is discontinued or after recombinant TSH administration. The presence of antithyroglobulin antibodies masks the real value of thyroglobulin and therefore, at the same time, antithyroglobulin antibodies should always be determined.
Inglese
Maussier, M. L., Danese, D., D'errico, G. F. L., Garganese, M., Pontecorvi, A., Lemmo, G., Clinical and laboratory follow-up in differentiated thyroid carcinoma, <<RAYS>>, 2000; 25 (2): 239-244 [http://hdl.handle.net/10807/13213]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/13213
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact